SOURCE-LINKED INTELLIGENCE
A simple blood test to choose the best treatment for each patient with depression.
ing for physicians and expensive to health care systems. RxMine revolutionizes this process by combining innovative stem cell technology, genetics, neurobiology, high-throughput screening and machine learning to test multiple antidepressants and screen drug effects using a patient-specific brain-in-a-dish model. RxMine identifies the optimal antidepressant for each patient and potentially reduces hospitalizations by 89%, emergency-room visits by 71% and depression related healthcare costs by 40% with savings up to 6,000 per patient per year. gene therapy,stem cell technology,biomarkers,neurobiology,CDSS,clinical decision support,drug screening platform,personalised medicine,blood,genetics,eHealth,drugs,antidepressants,Depression,stem cells
Read original source ↗ Open in workspace
- recordType
- award
- status
- SIGNED
- region
- EU
- value
- 2499000
- unit
- EUR
Evidence & attribution
European Commission, CORDIS Horizon Europe project dataset. Metadata adapted.
License: CORDIS reuse policy
First collected: 2026-09-20T00:21:03.701Z. This is not the publication date.